Adverse effects of<unk>  are similar to those of other AAS and include androgenic side effects like oily skin, acne, seborrhea, increased facial/body hair growth, scalp hair loss, and increased aggressiveness and sex drive. In women,<unk>  can cause partially irreversible virilization, for instance voice deepening, hirsutism, clitoromegaly, breast atrophy, and muscle hypertrophy, as well as menstrual disturbances and reversible infertility. In men, the medication may also cause hypogonadism, testicular atrophy, and reversible infertility at sufficiently high dosages.<unk>  can have adverse effects on the cardiovascular system, especially with long-term administration of high dosages. AAS like<unk>  stimulate erythropoiesis (red blood cell production) and increase hematocrit levels and at high dosages can cause polycythemia (overproduction of red blood cells), which can greatly increase the risk of thrombic events such as embolism and stroke. Unlike many other AAS,<unk>  is not aromatized into estrogens and hence has no risk of estrogenic side effects like gynecomastia, fluid retention, or edema. In addition, as it is not a 17α-alkylated AAS and is administered parenterally,<unk>  has no risk of hepatotoxicity. It has been theorized that<unk>  may have less risk of benign prostatic hyperplasia and prostate cancer than testosterone because it is not aromatized into estrogens. This is relevant because estrogens are thought to possibly be necessary for the manifestation of these diseases. In accordance,<unk>  has been found to not increase prostate gland size in men. Conversely, due to lack of aromatization into estrogens,<unk>  therapy for androgen replacement may result in decreased bone mineral density, incomplete effects in the brain, and undesirable changes in cholesterol levels.
Androstanolone
Cloxotestosterone acetate
Norethandrolone
Drostanolone propionate
Oxandrolone
Testosterone undecylenate
Testosterone cypionate
Nandrolone propionate